img

Global Opioid-Induced Constipation Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Opioid-Induced Constipation Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Opioid-Induced Constipation report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Opioid-Induced Constipation market is projected to reach US$ 3480.4 million in 2034, increasing from US$ 2531 million in 2022, with the CAGR of 4.6% during the period of 2024 to 2034. Demand from Hospital and Pharmacy are the major drivers for the industry.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Opioid-Induced Constipation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Segment by Application


Hospital
Pharmacy
Other

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Opioid-Induced Constipation market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Opioid-Induced Constipation, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Opioid-Induced Constipation industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Opioid-Induced Constipation in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Opioid-Induced Constipation introduction, etc. Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Opioid-Induced Constipation market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Opioid-Induced Constipation Market Overview
1.1 Opioid-Induced Constipation Product Overview
1.2 Opioid-Induced Constipation Market Segment by Type
1.2.1 Methylnaltrexone Bromide
1.2.2 Lubiprostone
1.2.3 Naloxegol
1.2.4 Others
1.3 Global Opioid-Induced Constipation Market Size by Type
1.3.1 Global Opioid-Induced Constipation Market Size Overview by Type (2018-2034)
1.3.2 Global Opioid-Induced Constipation Historic Market Size Review by Type (2018-2024)
1.3.3 Global Opioid-Induced Constipation Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Opioid-Induced Constipation Sales Breakdown by Type (2018-2024)
1.4.2 Europe Opioid-Induced Constipation Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Opioid-Induced Constipation Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Type (2018-2024)
2 Global Opioid-Induced Constipation Market Competition by Company
2.1 Global Top Players by Opioid-Induced Constipation Sales (2018-2024)
2.2 Global Top Players by Opioid-Induced Constipation Revenue (2018-2024)
2.3 Global Top Players by Opioid-Induced Constipation Price (2018-2024)
2.4 Global Top Manufacturers Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Product Type
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Opioid-Induced Constipation Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2022)
2.7 Date of Key Manufacturers Enter into Opioid-Induced Constipation Market
2.8 Key Manufacturers Opioid-Induced Constipation Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Opioid-Induced Constipation Status and Outlook by Region
3.1 Global Opioid-Induced Constipation Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Opioid-Induced Constipation Historic Market Size by Region
3.2.1 Global Opioid-Induced Constipation Sales in Volume by Region (2018-2024)
3.2.2 Global Opioid-Induced Constipation Sales in Value by Region (2018-2024)
3.2.3 Global Opioid-Induced Constipation Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Opioid-Induced Constipation Forecasted Market Size by Region
3.3.1 Global Opioid-Induced Constipation Sales in Volume by Region (2024-2034)
3.3.2 Global Opioid-Induced Constipation Sales in Value by Region (2024-2034)
3.3.3 Global Opioid-Induced Constipation Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Opioid-Induced Constipation by Application
4.1 Opioid-Induced Constipation Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.1.3 Other
4.2 Global Opioid-Induced Constipation Market Size by Application
4.2.1 Global Opioid-Induced Constipation Market Size Overview by Application (2018-2034)
4.2.2 Global Opioid-Induced Constipation Historic Market Size Review by Application (2018-2024)
4.2.3 Global Opioid-Induced Constipation Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Opioid-Induced Constipation Sales Breakdown by Application (2018-2024)
4.3.2 Europe Opioid-Induced Constipation Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Opioid-Induced Constipation Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Opioid-Induced Constipation Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Opioid-Induced Constipation Sales Breakdown by Application (2018-2024)
5 North America Opioid-Induced Constipation by Country
5.1 North America Opioid-Induced Constipation Historic Market Size by Country
5.1.1 North America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Opioid-Induced Constipation Sales in Volume by Country (2018-2024)
5.1.3 North America Opioid-Induced Constipation Sales in Value by Country (2018-2024)
5.2 North America Opioid-Induced Constipation Forecasted Market Size by Country
5.2.1 North America Opioid-Induced Constipation Sales in Volume by Country (2024-2034)
5.2.2 North America Opioid-Induced Constipation Sales in Value by Country (2024-2034)
6 Europe Opioid-Induced Constipation by Country
6.1 Europe Opioid-Induced Constipation Historic Market Size by Country
6.1.1 Europe Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Opioid-Induced Constipation Sales in Volume by Country (2018-2024)
6.1.3 Europe Opioid-Induced Constipation Sales in Value by Country (2018-2024)
6.2 Europe Opioid-Induced Constipation Forecasted Market Size by Country
6.2.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2024-2034)
6.2.2 Europe Opioid-Induced Constipation Sales in Value by Country (2024-2034)
7 Asia-Pacific Opioid-Induced Constipation by Region
7.1 Asia-Pacific Opioid-Induced Constipation Historic Market Size by Region
7.1.1 Asia-Pacific Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Opioid-Induced Constipation Forecasted Market Size by Region
7.2.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Opioid-Induced Constipation Sales in Value by Region (2024-2034)
8 Latin America Opioid-Induced Constipation by Country
8.1 Latin America Opioid-Induced Constipation Historic Market Size by Country
8.1.1 Latin America Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Opioid-Induced Constipation Sales in Volume by Country (2018-2024)
8.1.3 Latin America Opioid-Induced Constipation Sales in Value by Country (2018-2024)
8.2 Latin America Opioid-Induced Constipation Forecasted Market Size by Country
8.2.1 Latin America Opioid-Induced Constipation Sales in Volume by Country (2024-2034)
8.2.2 Latin America Opioid-Induced Constipation Sales in Value by Country (2024-2034)
9 Middle East and Africa Opioid-Induced Constipation by Country
9.1 Middle East and Africa Opioid-Induced Constipation Historic Market Size by Country
9.1.1 Middle East and Africa Opioid-Induced Constipation Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Opioid-Induced Constipation Forecasted Market Size by Country
9.2.1 Middle East and Africa Opioid-Induced Constipation Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Opioid-Induced Constipation Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Takeda Pharmaceuticals
10.1.1 Takeda Pharmaceuticals Company Information
10.1.2 Takeda Pharmaceuticals Introduction and Business Overview
10.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
10.1.5 Takeda Pharmaceuticals Recent Development
10.2 Bayer
10.2.1 Bayer Company Information
10.2.2 Bayer Introduction and Business Overview
10.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Bayer Opioid-Induced Constipation Products Offered
10.2.5 Bayer Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Sanofi Opioid-Induced Constipation Products Offered
10.3.5 Sanofi Recent Development
10.4 Mallinckrodt
10.4.1 Mallinckrodt Company Information
10.4.2 Mallinckrodt Introduction and Business Overview
10.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
10.4.5 Mallinckrodt Recent Development
10.5 Salix (Bausch Health)
10.5.1 Salix (Bausch Health) Company Information
10.5.2 Salix (Bausch Health) Introduction and Business Overview
10.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
10.5.5 Salix (Bausch Health) Recent Development
10.6 AstraZeneca
10.6.1 AstraZeneca Company Information
10.6.2 AstraZeneca Introduction and Business Overview
10.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
10.6.5 AstraZeneca Recent Development
10.7 Progenics Pharmaceuticals
10.7.1 Progenics Pharmaceuticals Company Information
10.7.2 Progenics Pharmaceuticals Introduction and Business Overview
10.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
10.7.5 Progenics Pharmaceuticals Recent Development
10.8 Purdue Pharm
10.8.1 Purdue Pharm Company Information
10.8.2 Purdue Pharm Introduction and Business Overview
10.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
10.8.5 Purdue Pharm Recent Development
10.9 Nektar Therapeutics
10.9.1 Nektar Therapeutics Company Information
10.9.2 Nektar Therapeutics Introduction and Business Overview
10.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
10.9.5 Nektar Therapeutics Recent Development
10.10 Daiichi Sankyo
10.10.1 Daiichi Sankyo Company Information
10.10.2 Daiichi Sankyo Introduction and Business Overview
10.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
10.10.5 Daiichi Sankyo Recent Development
10.11 Prestige
10.11.1 Prestige Company Information
10.11.2 Prestige Introduction and Business Overview
10.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Prestige Opioid-Induced Constipation Products Offered
10.11.5 Prestige Recent Development
10.12 GSK
10.12.1 GSK Company Information
10.12.2 GSK Introduction and Business Overview
10.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.12.4 GSK Opioid-Induced Constipation Products Offered
10.12.5 GSK Recent Development
10.13 Shionogi
10.13.1 Shionogi Company Information
10.13.2 Shionogi Introduction and Business Overview
10.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Shionogi Opioid-Induced Constipation Products Offered
10.13.5 Shionogi Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Opioid-Induced Constipation Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Opioid-Induced Constipation Industrial Chain Analysis
11.4 Opioid-Induced Constipation Market Dynamics
11.4.1 Opioid-Induced Constipation Industry Trends
11.4.2 Opioid-Induced Constipation Market Drivers
11.4.3 Opioid-Induced Constipation Market Challenges
11.4.4 Opioid-Induced Constipation Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Opioid-Induced Constipation Distributors
12.3 Opioid-Induced Constipation Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Methylnaltrexone Bromide
Table 2. Major Company of Lubiprostone
Table 3. Major Company of Naloxegol
Table 4. Major Company of Others
Table 5. Global Opioid-Induced Constipation Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Opioid-Induced Constipation Sales by Type (2018-2024) & (K Units)
Table 7. Global Opioid-Induced Constipation Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Opioid-Induced Constipation Sales by Type (2018-2024) & (US& Million)
Table 9. Global Opioid-Induced Constipation Market Share in Value by Type (2018-2024)
Table 10. Global Opioid-Induced Constipation Price by Type (2018-2024) & (USD/Unit)
Table 11. Global Opioid-Induced Constipation Sales by Type (2024-2034) & (K Units)
Table 12. Global Opioid-Induced Constipation Sales Market Share in Volume by Type (2024-2034)
Table 13. Global Opioid-Induced Constipation Sales by Type (2024-2034) & (US$ Million)
Table 14. Global Opioid-Induced Constipation Sales Market Share in Value by Type (2024-2034)
Table 15. Global Opioid-Induced Constipation Price by Type (2024-2034) & (USD/Unit)
Table 16. North America Opioid-Induced Constipation Sales by Type (2018-2024) & (K Units)
Table 17. North America Opioid-Induced Constipation Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Opioid-Induced Constipation Sales (K Units) by Type (2018-2024)
Table 19. Europe Opioid-Induced Constipation Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Opioid-Induced Constipation Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Opioid-Induced Constipation Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Opioid-Induced Constipation Sales (K Units) by Type (2018-2024)
Table 23. Latin America Opioid-Induced Constipation Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Opioid-Induced Constipation Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Opioid-Induced Constipation Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Opioid-Induced Constipation Sales by Company (2018-2024) & (K Units)
Table 27. Global Opioid-Induced Constipation Sales Share by Company (2018-2024)
Table 28. Global Opioid-Induced Constipation Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Opioid-Induced Constipation Revenue Share by Company (2018-2024)
Table 30. Global Market Opioid-Induced Constipation Price by Company (2018-2024) & (USD/Unit)
Table 31. Global Opioid-Induced Constipation Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2022)
Table 34. Date of Key Manufacturers Enter into Opioid-Induced Constipation Market
Table 35. Key Manufacturers Opioid-Induced Constipation Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Opioid-Induced Constipation Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Global Opioid-Induced Constipation Sales by Region (2018-2024) & (K Units)
Table 39. Global Opioid-Induced Constipation Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Opioid-Induced Constipation Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Opioid-Induced Constipation Sales Market Share in Value by Region (2018-2024)
Table 42. Global Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 43. Global Opioid-Induced Constipation Sales by Region (2024-2034) & (K Units)
Table 44. Global Opioid-Induced Constipation Sales Market Share in Volume by Region (2024-2034)
Table 45. Global Opioid-Induced Constipation Sales by Region (2024-2034) & (US$ Million)
Table 46. Global Opioid-Induced Constipation Sales Market Share in Value by Region (2024-2034)
Table 47. Global Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 48. Global Opioid-Induced Constipation Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 49. Global Opioid-Induced Constipation Sales by Application (2018-2024) & (K Units)
Table 50. Global Opioid-Induced Constipation Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Opioid-Induced Constipation Sales Market Share in Value by Application (2018-2024)
Table 53. Global Opioid-Induced Constipation Price by Application (2018-2024) & (USD/Unit)
Table 54. Global Opioid-Induced Constipation Sales by Application (2024-2034) & (K Units)
Table 55. Global Opioid-Induced Constipation Sales Market Share in Volume by Application (2024-2034)
Table 56. Global Opioid-Induced Constipation Sales by Application (2024-2034) & (US$ Million)
Table 57. Global Opioid-Induced Constipation Sales Market Share in Value by Application (2024-2034)
Table 58. Global Opioid-Induced Constipation Price by Application (2024-2034) & (USD/Unit)
Table 59. North America Opioid-Induced Constipation Sales by Application (2018-2024) (K Units)
Table 60. North America Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Opioid-Induced Constipation Sales by Application (2018-2024) (K Units)
Table 62. Europe Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Opioid-Induced Constipation Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Opioid-Induced Constipation Sales by Application (2018-2024) (K Units)
Table 66. Latin America Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Opioid-Induced Constipation Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Opioid-Induced Constipation Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Opioid-Induced Constipation Sales by Country (2018-2024) & (K Units)
Table 70. North America Opioid-Induced Constipation Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Opioid-Induced Constipation Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Opioid-Induced Constipation Sales Market Share in Value by Country (2018-2024)
Table 73. North America Opioid-Induced Constipation Sales by Country (2024-2034) & (K Units)
Table 74. North America Opioid-Induced Constipation Sales Market Share in Volume by Country (2024-2034)
Table 75. North America Opioid-Induced Constipation Sales by Country (2024-2034) & (US$ Million)
Table 76. North America Opioid-Induced Constipation Sales Market Share in Value by Country (2024-2034)
Table 77. Europe Opioid-Induced Constipation Sales by Country (2018-2024) & (K Units)
Table 78. Europe Opioid-Induced Constipation Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Opioid-Induced Constipation Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Opioid-Induced Constipation Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Opioid-Induced Constipation Sales by Country (2024-2034) & (K Units)
Table 82. Europe Opioid-Induced Constipation Sales Market Share in Volume by Country (2024-2034)
Table 83. Europe Opioid-Induced Constipation Sales by Country (2024-2034) & (US$ Million)
Table 84. Europe Opioid-Induced Constipation Sales Market Share in Value by Country (2024-2034)
Table 85. Asia-Pacific Opioid-Induced Constipation Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Opioid-Induced Constipation Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Opioid-Induced Constipation Sales by Region (2024-2034) & (K Units)
Table 90. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Region (2024-2034)
Table 91. Asia-Pacific Opioid-Induced Constipation Sales by Region (2024-2034) & (US$ Million)
Table 92. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Region (2024-2034)
Table 93. Latin America Opioid-Induced Constipation Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Opioid-Induced Constipation Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Opioid-Induced Constipation Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Opioid-Induced Constipation Sales by Country (2024-2034) & (K Units)
Table 98. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Country (2024-2034)
Table 99. Latin America Opioid-Induced Constipation Sales by Country (2024-2034) & (US$ Million)
Table 100. Latin America Opioid-Induced Constipation Sales Market Share in Value by Country (2024-2034)
Table 101. Middle East and Africa Opioid-Induced Constipation Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Opioid-Induced Constipation Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Opioid-Induced Constipation Sales by Country (2024-2034) & (K Units)
Table 106. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Volume by Country (2024-2034)
Table 107. Middle East and Africa Opioid-Induced Constipation Sales by Country (2024-2034) & (US$ Million)
Table 108. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Country (2024-2034)
Table 109. Takeda Pharmaceuticals Company Information
Table 110. Takeda Pharmaceuticals Introduction and Business Overview
Table 111. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 112. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 113. Takeda Pharmaceuticals Recent Development
Table 114. Bayer Company Information
Table 115. Bayer Introduction and Business Overview
Table 116. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 117. Bayer Opioid-Induced Constipation Product
Table 118. Bayer Recent Development
Table 119. Sanofi Company Information
Table 120. Sanofi Introduction and Business Overview
Table 121. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 122. Sanofi Opioid-Induced Constipation Product
Table 123. Sanofi Recent Development
Table 124. Mallinckrodt Company Information
Table 125. Mallinckrodt Introduction and Business Overview
Table 126. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 127. Mallinckrodt Opioid-Induced Constipation Product
Table 128. Mallinckrodt Recent Development
Table 129. Salix (Bausch Health) Company Information
Table 130. Salix (Bausch Health) Introduction and Business Overview
Table 131. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 132. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 133. Salix (Bausch Health) Recent Development
Table 134. AstraZeneca Company Information
Table 135. AstraZeneca Introduction and Business Overview
Table 136. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 137. AstraZeneca Opioid-Induced Constipation Product
Table 138. AstraZeneca Recent Development
Table 139. Progenics Pharmaceuticals Company Information
Table 140. Progenics Pharmaceuticals Introduction and Business Overview
Table 141. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 142. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 143. Progenics Pharmaceuticals Recent Development
Table 144. Purdue Pharm Company Information
Table 145. Purdue Pharm Introduction and Business Overview
Table 146. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 147. Purdue Pharm Opioid-Induced Constipation Product
Table 148. Purdue Pharm Recent Development
Table 149. Nektar Therapeutics Company Information
Table 150. Nektar Therapeutics Introduction and Business Overview
Table 151. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 152. Nektar Therapeutics Opioid-Induced Constipation Product
Table 153. Nektar Therapeutics Recent Development
Table 154. Daiichi Sankyo Company Information
Table 155. Daiichi Sankyo Introduction and Business Overview
Table 156. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 157. Daiichi Sankyo Opioid-Induced Constipation Product
Table 158. Daiichi Sankyo Recent Development
Table 159. Prestige Company Information
Table 160. Prestige Introduction and Business Overview
Table 161. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 162. Prestige Opioid-Induced Constipation Product
Table 163. Prestige Recent Development
Table 164. GSK Company Information
Table 165. GSK Introduction and Business Overview
Table 166. GSK Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 167. GSK Opioid-Induced Constipation Product
Table 168. GSK Recent Development
Table 169. Shionogi Company Information
Table 170. Shionogi Introduction and Business Overview
Table 171. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 172. Shionogi Opioid-Induced Constipation Product
Table 173. Shionogi Recent Development
Table 174. Key Raw Materials Lists
Table 175. Raw Materials Key Suppliers Lists
Table 176. Opioid-Induced Constipation Market Trends
Table 177. Opioid-Induced Constipation Market Drivers
Table 178. Opioid-Induced Constipation Market Challenges
Table 179. Opioid-Induced Constipation Market Restraints
Table 180. Opioid-Induced Constipation Distributors List
Table 181. Opioid-Induced Constipation Downstream Customers
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid-Induced Constipation Product Picture
Figure 2. Global Opioid-Induced Constipation Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Opioid-Induced Constipation Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Opioid-Induced Constipation Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of Methylnaltrexone Bromide
Figure 6. Global Methylnaltrexone Bromide Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of Lubiprostone
Figure 8. Global Lubiprostone Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of Naloxegol
Figure 10. Global Naloxegol Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 13. Global Opioid-Induced Constipation Sales by Type (2018-2034) & (US$ Million)
Figure 14. Global Opioid-Induced Constipation Sales Market Share by Type in 2022 & 2034
Figure 15. North America Opioid-Induced Constipation Sales Market Share in Volume by Type in 2022
Figure 16. North America Opioid-Induced Constipation Sales Market Share in Value by Type in 2022
Figure 17. Europe Opioid-Induced Constipation Sales Market Share in Volume by Type in 2022
Figure 18. Europe Opioid-Induced Constipation Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Type in 2022
Figure 21. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Opioid-Induced Constipation Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Opioid-Induced Constipation Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Opioid-Induced Constipation Revenue in 2022
Figure 27. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Hospital
Figure 29. Global Hospital Sales YoY Growth (2018-2034) & (K Units)
Figure 30. Product Picture of Pharmacy
Figure 31. Global Pharmacy Sales YoY Growth (2018-2034) & (K Units)
Figure 32. Product Picture of Other
Figure 33. Global Other Sales YoY Growth (2018-2034) & (K Units)
Figure 34. Global Opioid-Induced Constipation Sales by Application (2018-2034) & (US$ Million)
Figure 35. Global Opioid-Induced Constipation Sales Market Share by Application in 2022 & 2034
Figure 36. North America Opioid-Induced Constipation Sales Market Share in Volume by Application in 2022
Figure 37. North America Opioid-Induced Constipation Sales Market Share in Value by Application in 2022
Figure 38. Europe Opioid-Induced Constipation Sales Market Share in Volume by Application in 2022
Figure 39. Europe Opioid-Induced Constipation Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Opioid-Induced Constipation Sales Market Share in Value by Application in 2022
Figure 42. Latin America Opioid-Induced Constipation Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Opioid-Induced Constipation Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Opioid-Induced Constipation Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Opioid-Induced Constipation Manufacturing Cost Structure
Figure 47. Opioid-Induced Constipation Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries